Search Results for "Drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug. Results 2501 to 2510 of 2593 total matches.
In Brief: Dapagliflozin (Farxiga) for Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Jul 26, 2021 (Issue 1629)
. All rights reserved. ©2021. www.fdbhealth.
com/policies/drug-pricing-policy. Forxiga chronic kidney disease ...
The sodium-glucose cotransporter 2 (SGLT2) inhibitor
dapagliflozin (Farxiga – AstraZeneca) has been
approved by the FDA for treatment of adults with
chronic kidney disease (CKD) at risk of progression
(not defined in the label). Dapagliflozin is the first
SGLT2 inhibitor to be approved in the US for treatment
of CKD.
In Brief: Doxycycline for STI Post-Exposure Prophylaxis
The Medical Letter on Drugs and Therapeutics • Jul 22, 2024 (Issue 1707)
of the drug could increase the incidence of nasal colonization with tetracycline-resistant Staphylococcus ...
The CDC has issued a recommendation for use
of a single dose of doxycycline for post-exposure
prophylaxis (PEP) of bacterial sexually transmitted
infections (STIs), specifically syphilis, chlamydia, and
gonorrhea, in men who have sex with men (MSM) and
transgender women (TGW) who had a bacterial STI
within the previous 12 months.
Med Lett Drugs Ther. 2024 Jul 22;66(1707):119-20 doi:10.58347/tml.2024.1707f | Show Introduction Hide Introduction
Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Chronic Weight Management (online only)
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024 (Issue 1708)
pancreatitis and acute gall bladder disease
Drug Eligible Patients Usual Dosage Other Information
GLP-1 ...
View the Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Chronic Weight Management
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e1-2 doi:10.58347/tml.2024.1708d | Show Introduction Hide Introduction
Sunscreens
The Medical Letter on Drugs and Therapeutics • Jun 23, 2025 (Issue 1731)
: sunscreen drug products for
OTC human use. September 24, 2021. Available at: https://bit.
ly/3SVWg3n.gov ...
Excessive exposure to ultraviolet (UV) radiation can
cause erythema, photoaging, and skin cancer.
Sunscreens are widely used to reduce these risks, but
questions remain about their effectiveness and safety.
In 2021, the FDA proposed a rule that would require
additional safety studies for some sunscreen active
ingredients and mandate better UVA protection in
sunscreen products.
Med Lett Drugs Ther. 2025 Jun 23;67(1731):97-102 doi:10.58347/tml.2025.1731a | Show Introduction Hide Introduction
Dexamethasone Bacterial Meningitis In Children
The Medical Letter on Drugs and Therapeutics • Jan 27, 1989 (Issue 784)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
A recent report in the New England Journal of Medicine suggested that in children with bacterial meningitis, adding the corticosteroid dexamethasone (Decadron; and others) to antibiotic treatment could decrease the incidence of moderate or severe hearing loss.
Balloon Dilatation Of The Prostate
The Medical Letter on Drugs and Therapeutics • Jun 29, 1990 (Issue 821)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
To avoid the morbidity and occasional mortality of transurethral resection or open prostatectomy, some urologists are now using balloon dilatation of the prostatic urethra to treat benign prostatic hypertrophy.
Safe Needles
The Medical Letter on Drugs and Therapeutics • Apr 05, 1991 (Issue 841)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Accidental needlesticks can lead to infection with hepatitis viruses, human immunodeficiency virus, and other blood-borne bacterial, viral, and fungal pathogens (DK Henderson et al, Ann Intern Med, 113:740, 1990). Re-capping used needles is the most frequent cause of needlestick injuries (J Jagger et al, N Engl J Med, 319:284, 1988; MH Becker et al, Am J Infect Control, 18:232, 1990).
St. John's Wort
The Medical Letter on Drugs and Therapeutics • Nov 21, 1997 (Issue 1014)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Many readers have asked the Medical Letter to evaluate St. John's wort, an herbal extract now widely sold in health food stores and pharmacies, for its effectiveness and safety in the treatment of depression. St. John's wort is licensed in Germany for treatment of anxiety, depression and insomnia. In the USA, it is considered a dietary supplement and has not been evaluated by the FDA.
The Crystal Ear Hearing Aid
The Medical Letter on Drugs and Therapeutics • Jun 05, 1998 (Issue 1028)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Full-page advertisements in The New York Times and other newspapers have promoted use of the Crystal Ear hearing aid as an inexpensive rememdy for people with impaired hearing. Some patients may be asking their physicians about these devices.
A Percutaneous Device (MitraClip) for Mitral Regurgitation
The Medical Letter on Drugs and Therapeutics • Dec 23, 2013 (Issue 1432)
The Medical Letter®
On Drugs and Therapeutics
Volume 55 (Issue 1432)
December 23, 2013 ...
The FDA has approved the use of a transcatheter
mitral valve device (MitraClip – Abbott) for percutaneous
treatment of significant symptomatic degenerative
mitral regurgitation (grade 3-4+) in patients who
are at prohibitive risk for mitral valve surgery. It is the
first percutaneous nonsurgical treatment approved for
this indication.